AVITA MEDICAL Business Summary

AVITA Medical Inc. (RCEL) is a commercial-stage regenerative medicine company that generates revenue primarily through the transactional sale of its proprietary RECELL System, an autologous cell harvesting device used to prepare and deliver "Spray-On Skin" at the point of care. The company’s business model is centered on the acute wound care segment, specifically targeting thermal burns, trauma, and surgical wounds. In 2025 and early 2026, AVITA expanded its portfolio into a multi-product platform by integrating Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix, to address the broader $2 billion soft-tissue reconstruction market. Direct competitors include Organogenesis Holdings, Integra LifeSciences, MiMedx Group, and Smith & Nephew. AVITA distinguishes itself as a specialized leader in point-of-care autologous therapies, offering a unique bedside processing advantage that reduces the need for traditional donor-site skin grafting compared to its competitors' off-the-shelf or lab-grown alternatives. The company was founded by world-renowned plastic surgeon Professor Fiona Wood and scientist Marie Stoner, who pioneered the "spray-on skin" technology in Australia following the 2002 Bali bombings. As of February 2026, the leadership team is headed by Interim CEO and Chairman Cary Vance, a 30-year healthcare veteran with prior chief executive roles at Titan Medical and Hansen Medical, alongside experience at GE HealthCare and Covidien. Supporting him is CFO David O’Toole, who brought over three decades of life sciences financial expertise from Opiant Pharmaceuticals and Deloitte & Touche upon joining in 2023. The company is backed by notable institutional investor Perceptive Advisors LLC, which recently provided a $60 million credit facility to support the firm's transition toward cash-flow breakeven, and its board includes experienced directors such as Lead Independent Director Jan Stern Reed and healthcare investor Jeremy Curnock Cook.